Chronic Myeloid Leukemia

Ponatinib Produces High Response Rates in CML (08-13-2012)

Ponatinib, an investigational targeted agent, appears to be significantly effective in treatment-refractory chronic myeloid leukemia (CML) and produces early and lasting responses, according to the preliminary results of a study presented at the 2012... Continue Reading

New Warning Added to Sprycel Label (10-17-2011)

The US Food and Drug Administration (FDA) announced that Sprycel® (dasatinib) may increase the risk of a rare but serious condition known as pulmonary arterial hypertension. Sprycel is a targeted therapy used to treat selected adult patients with Philadelphia... Continue Reading

Bosutinib Shows Promise for Second-Line CML Treatment (10-14-2011)

Treatment with the investigational drug bosutinib produced promising rates of response among patients with chronic-phase chronic myeloid leukemia (CML) that had previously been treated with Gleevec® (imatinib). The results of this Phase I/II trial were... Continue Reading

Tasigna Continues to Show Benefit for Newly Diagnosed CML (09-7-2011)

According to updated results from a Phase III clinical trial, Tasigna® (nilotinib) continues to be more effective than Gleevec® (imatinib) for the initial treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid... Continue Reading

Bosutinib Evaluated for Initial Treatment of Patients with CML (06-17-2011)

Researchers involved in an international study have reported that a new tyrosine kinase inhibitor, bosutinib, appears to be superior to Gleevec® (imatinib) for the initial therapy of patients with chronic myeloid leukemia (CML). The early results of... Continue Reading

Many Patients with “Chemo Brain” Recover within Five Years (05-23-2011)

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients. For some patients, however, symptoms may persist... Continue Reading

CML Patients Treated with Gleevec Have Normal Life Expectancy (03-31-2011)

People with chronic myeloid leukemia (CML) that is in complete remission after two years of treatment with Gleevec® (imatinib) have survival rates that are similar to those of the general population. These results were published in the Journal of the... Continue Reading

Tasigna Improves Outcomes in Newly Diagnosed CML (12-10-2010)

According to updated results from a Phase III clinical trial, Tasigna® (nilotinib) continues to be more effective than Gleevec® (imatinib) for the initial treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid... Continue Reading

Sprycel® Approved for Initial Treatment of Chronic Myeloid Leukemia (11-5-2010)

The U.S. Food and Drug Administration has expanded the approval of Sprycel® (dasatinib) to include the initial treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.[1] Each year in the United States, approximately... Continue Reading

Tasigna Approved for Initial Treatment of Chronic Myeloid Leukemia (06-22-2010)

The U.S. Food and Drug Administration has expanded the approval of Tasigna® (nilotinib) to include the initial treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. Each year in the United States, approximately... Continue Reading

« Previous PageNext Page »